SLC35A1 Antibody

What is SLC35A1 and what cellular functions does it perform?

SLC35A1, also known as CMP-sialic acid transporter (CMPST), is responsible for transferring CMP-sialic acid from the cytosol through Golgi membranes, thus playing a vital role in the terminal sialylation of glycan structures . As a member of the solute carrier family 35, it is specifically localized to the Golgi apparatus where it facilitates the transport of activated sialic acid for use by sialyltransferases within the Golgi lumen . The protein has a calculated molecular weight of 37 kDa (337 amino acids) though it is typically observed at 30-33 kDa in experimental conditions . SLC35A1 is essential for proper glycoprotein processing, and its dysfunction can lead to significant alterations in cell surface glycan patterns, particularly affecting α2,6-linked sialic acid expression .

What experimental applications are SLC35A1 antibodies validated for?

SLC35A1 antibodies have been validated for multiple experimental applications with specific dilution recommendations:

The antibody's reactivity has been confirmed in human, mouse, and rat samples, making it versatile for comparative studies across species .

What positive controls are recommended for validating SLC35A1 antibody performance?

Researchers should consider using tissues and cell lines with known SLC35A1 expression. According to validation data, positive IHC detection has been achieved in mouse spleen tissue, mouse testis tissue, human skin tissue, and human spleen tissue . For immunofluorescence applications, HepG2 cells have shown positive detection and can serve as a reliable positive control . When establishing experimental protocols, it is advisable to include both positive tissue controls and negative controls (such as SLC35A1 knockout cell lines if available) to ensure antibody specificity and optimize staining conditions .

What is the recommended storage and handling protocol for SLC35A1 antibodies?

For optimal antibody performance and longevity, SLC35A1 antibodies should be stored at -20°C, where they remain stable for one year after shipment . The antibodies are typically provided in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . It's important to note that aliquoting is generally unnecessary for -20°C storage of these antibodies, reducing handling complications . When working with smaller quantities (20μl sizes), be aware that they may contain 0.1% BSA as a stabilizer . As with all antibodies containing sodium azide, proper handling precautions should be observed as it is classified as a hazardous substance .

How does SLC35A1 knockout affect cellular sialylation patterns and what methodologies can detect these changes?

SLC35A1 knockout results in distinctive alterations to cellular sialylation patterns that can be characterized through lectin staining methodologies. Studies have demonstrated that SLC35A1 knockout nearly abolishes the expression of α2,6-linked sialic acid on cell surfaces, as evidenced by negative staining with Sambucus nigra lectin (SNA) . Quantitatively, flow cytometry analysis shows that SLC35A1 knockout decreases α2,6-linked sialic acid expression by approximately 90% .

In contrast, the effect on α2,3-linked sialic acid is less severe, with a reduction of about 64% as detected by Maackia amurensis lectin II (MAL II) staining . This differential impact suggests distinct trafficking pathways for different sialic acid linkages. Interestingly, the reduction in sialic acid expression following SLC35A1 knockout correlates with increased expression of terminal galactose residues, which can be detected using Erythrina cristagalli lectin (ECL) staining . These changes in glycan presentation have significant functional consequences, particularly for interactions with proteins and pathogens that recognize specific glycan structures.

What role does SLC35A1 play in AAV vector transduction and what are the implications for gene therapy research?

SLC35A1 has been identified as a critical host factor for adeno-associated virus (AAV) trafficking, with significant implications for gene therapy applications. Research has demonstrated that SLC35A1 knockout significantly decreases transduction efficiency of multiple AAV serotypes, including AAV2, AAV5, and the airway-tropic variant AAV2.5T .

The mechanism appears to be primarily post-entry, affecting intracellular trafficking rather than initial binding. Specifically, SLC35A1 knockout significantly diminishes vector nuclear import, a critical step for successful transduction . Notably, while SLC35A1 knockout decreased transduction of most AAV serotypes (AAV1-8, AAV12, and AAV13), it actually increased transduction of AAV9 and AAV11 . This differential effect correlates with the primary attachment mechanisms of these serotypes - AAV9 and AAV11 primarily utilize galactose for cell attachment, which shows increased expression in SLC35A1 knockout cells .

For gene therapy applications, these findings suggest:

• SLC35A1 expression levels could be used as biomarkers to predict AAV transduction efficiency

• Temporary modulation of SLC35A1 activity might enhance specific AAV serotype transduction

• Vector design strategies could be developed to circumvent SLC35A1 dependency

How can researchers differentiate between the transporter function and trafficking function of SLC35A1?

Distinguishing between SLC35A1's transporter function (CMP-sialic acid transport) and its potential role in intracellular trafficking requires sophisticated experimental approaches:

• Domain-specific mutants: Research has shown that the C-terminal cytoplasmic tail deletion (ΔC Tail) mutant of SLC35A1 does not drastically decrease sialic acid expression but significantly decreases AAV transduction and vector nuclear import . This suggests the C-tail is specifically critical for trafficking functions distinct from sialic acid transport.

• Point mutation analysis: The T128A mutant of SLC35A1 significantly decreases sialic acid expression but still supports AAV transduction and nuclear import . This indicates that specific amino acid residues may differentially affect transporter versus trafficking functions.

• Co-immunoprecipitation studies: To identify proteins that interact with SLC35A1 during vesicular trafficking versus those involved in transport function, researchers can perform co-IP experiments followed by mass spectrometry using either wild-type SLC35A1 or specific mutants.

• Live-cell imaging: Using fluorescently tagged SLC35A1 variants in combination with markers for different organelles can help visualize and quantify the protein's involvement in trafficking pathways.

These experimental approaches help delineate the dual roles of SLC35A1 in both sialic acid transport and intracellular trafficking processes.

What methodological approaches can be used to study SLC35A1 in polarized epithelial cells?

Studying SLC35A1 in polarized epithelial cells presents unique challenges but offers valuable insights into its physiological functions. Human airway epithelium culture at an air-liquid interface (HAE-ALI) represents a physiologically relevant model for investigating SLC35A1 function in polarized cells . In this model system, researchers can:

• Generate CRISPR-mediated SLC35A1 knockout cultures: This allows for the functional assessment of SLC35A1 in a polarized epithelium that closely mimics in vivo conditions .

• Assess vector binding, internalization, and transduction: Studies in HAE-ALI cultures have shown that SLC35A1 knockout results in a 38% decrease in AAV5 binding, 26% reduction in vector internalization, but a drastic 98% decrease in vector transduction . For AAV2.5T, SLC35A1 knockout had no significant effect on binding or entry but decreased transduction by 76% .

• Perform domain-specific analyses: By introducing mutant forms of SLC35A1 into knockout cultures, researchers can assess the importance of specific protein domains in polarized cells.

• Conduct apical versus basolateral trafficking studies: Given the polarized nature of epithelial cells, researchers can investigate whether SLC35A1 differentially affects protein trafficking to apical versus basolateral membranes.

• Analyze glycan profiles: Using lectins specific for differently linked sialic acids, researchers can determine how SLC35A1 affects glycan presentation on different membrane domains of polarized cells.

What are the key considerations for optimizing antigen retrieval when using SLC35A1 antibodies for IHC?

Optimal antigen retrieval is crucial for successful immunohistochemical detection of SLC35A1. The primary recommendation is to use TE buffer at pH 9.0, which has been validated for various tissue types including mouse spleen, mouse testis, human skin, and human spleen tissues . As an alternative approach, citrate buffer at pH 6.0 can also be used, though this may yield different staining intensity and patterns .

When optimizing antigen retrieval protocols, researchers should consider:

• Tissue fixation method: Overfixation can mask epitopes and require more aggressive retrieval conditions.

• Tissue type: Different tissues may require adjusted retrieval conditions due to varying protein content and tissue density.

• Section thickness: Thicker sections typically require longer retrieval times.

• Retrieval time: Begin with manufacturer recommendations and adjust as needed (typically 10-20 minutes).

• Temperature control: Consistent temperature during retrieval is critical for reproducible results.

A systematic approach comparing both retrieval methods across a range of conditions (time, temperature) using known positive control tissues is recommended for achieving optimal staining with minimal background.

How can researchers validate that an observed phenotype is specifically due to SLC35A1 knockout rather than off-target effects?

When attributing phenotypes to SLC35A1 knockout, researchers should implement several validation approaches to rule out off-target effects:

• Multiple guide RNA strategies: Using different guide RNAs targeting distinct regions of the SLC35A1 gene can help confirm that the observed phenotype is consistently associated with SLC35A1 disruption .

• Complementation studies: Reintroducing wild-type SLC35A1 into knockout cells should rescue the phenotype if it is specifically due to SLC35A1 deficiency . This can be achieved using lentiviral vectors expressing SLC35A1 under a suitable promoter.

• Domain-specific rescue: Expressing specific SLC35A1 mutants (such as the ΔC Tail or T128A mutants) in knockout cells can determine which protein domains are responsible for particular aspects of the phenotype .

• Protein verification: Western blotting should confirm the absence of SLC35A1 protein in knockout cell lines . Additionally, immunofluorescence staining can verify the complete absence of the protein at the cellular level.

• Phenotypic complementation: In systems where SLC35A1 knockout affects complex phenotypes like AAV transduction, researchers can verify specificity by demonstrating that the addition of purified sialyltransferases or other glycosylation pathway components does not rescue the phenotype, indicating it's specifically related to SLC35A1's function.

What experimental design is recommended for studying the temporal dynamics of SLC35A1 function?

Investigating the temporal dynamics of SLC35A1 function requires experimental approaches that allow for controlled modulation of SLC35A1 activity:

• Inducible knockout/knockdown systems: Using Tet-On/Off systems or other inducible CRISPR approaches allows researchers to control the timing of SLC35A1 depletion, enabling the study of immediate versus long-term consequences.

• Pulse-chase experiments: Labeling newly synthesized sialylated glycoproteins using metabolic incorporation of modified sialic acids can help track how quickly SLC35A1 disruption affects the sialylation of newly synthesized versus existing glycoproteins.

• Live cell imaging: Using fluorescently tagged SLC35A1 constructs combined with Golgi markers allows monitoring of protein localization and trafficking in real-time.

• Time-course glycan analysis: Lectin-based flow cytometry at different time points following SLC35A1 disruption can reveal how quickly surface sialylation patterns change .

• Temporal requirements in AAV transduction: Introducing SLC35A1 at different time points relative to AAV infection can help determine when SLC35A1 function is most critical for successful viral trafficking and transduction .

• Pharmacological modulation: Using specific inhibitors of SLC35A1 with defined administration schedules can provide insights into acute versus chronic effects of transporter inhibition.

How does SLC35A1 function compare with other sialic acid transporters in the SLC35 family?

The SLC35 family includes several transporters involved in nucleotide sugar transport, with SLC35A1 specifically responsible for CMP-sialic acid transport. A comparative analysis reveals important distinctions:

What distinguishes SLC35A1 is its specific impact on terminal sialylation patterns, particularly α2,6-linked sialic acids, while having a less pronounced effect on α2,3-linked sialic acids . This suggests potential compensatory mechanisms or alternative transport pathways for certain sialic acid linkages. Additionally, SLC35A1 appears to have functions beyond its canonical transport role, as evidenced by its involvement in AAV trafficking that cannot be fully explained by changes in sialylation alone .

What are the implications of SLC35A1 expression patterns across different tissues for targeted research applications?

SLC35A1 expression varies across tissues, with implications for research design and interpretation:

• Tissue-specific validation: Positive IHC detection has been confirmed in mouse spleen, mouse testis, human skin, and human spleen tissues . Researchers should consider these tissues as positive controls when establishing new detection protocols.

• Cell type heterogeneity: Within tissues, SLC35A1 expression may vary between cell types. For example, in polarized airway epithelium, SLC35A1 function appears particularly critical for AAV vector transduction .

• Experimental model selection: When studying SLC35A1 function in disease contexts, researchers should select models that appropriately reflect the expression patterns in the target tissue. Human airway epithelium culture at an air-liquid interface (HAE-ALI) represents one such physiologically relevant model for respiratory research .

• Differential effects on viral vectors: The impact of SLC35A1 on AAV serotype transduction varies significantly, with profound inhibition of AAV5 transduction but enhancement of AAV9 and AAV11 transduction . This suggests tissue-specific SLC35A1 expression could influence viral tropism in gene therapy applications.

• Application-specific considerations: For gene therapy applications targeting specific tissues, understanding the differential expression and function of SLC35A1 could inform vector selection and design strategies to maximize transduction efficiency.

How can multi-omics approaches enhance our understanding of SLC35A1 function in complex biological systems?

Integrating multiple omics approaches provides a comprehensive understanding of SLC35A1 function beyond what can be achieved through individual techniques:

• Glycomics + Transcriptomics: Combining glycan profiling with RNA-seq in SLC35A1-manipulated systems can reveal which sialylated glycoproteins are most affected and identify potential compensatory mechanisms activated upon SLC35A1 disruption.

• Proteomics + Interactomics: Mass spectrometry-based identification of SLC35A1 binding partners, particularly for different functional domains like the C-terminal tail that affects AAV trafficking , can elucidate the protein's non-canonical functions.

• Glycoproteomics: Site-specific glycan analysis of proteins in normal versus SLC35A1-deficient cells can identify which glycoproteins and which glycosylation sites are most dependent on SLC35A1 function.

• Spatial Transcriptomics + Glycan Imaging: Combining spatial transcriptomic data on SLC35A1 expression with lectin-based imaging of tissue sections can reveal spatial relationships between transporter expression and glycosylation patterns.

• Systems Biology Modeling: Integrating multi-omics data into computational models of glycosylation pathways can predict how perturbations in SLC35A1 function might ripple through cellular systems and affect multiple processes beyond glycosylation.

• Comparative Genomics: Analyzing SLC35A1 conservation and variation across species in conjunction with glycan profiles can provide evolutionary insights into the divergent functions of this transporter.

What are the implications of SLC35A1's role in viral trafficking for infectious disease and gene therapy research?

The discovery that SLC35A1 plays a critical role in AAV trafficking independent of its sialylation function opens new research avenues with significant implications:

• Vector optimization: Understanding how SLC35A1 affects different AAV serotypes can inform the design of vectors with enhanced transduction efficiency . For example, vectors that bypass SLC35A1 dependency might show improved performance in tissues with low SLC35A1 expression.

• Host factor modulation: Temporary modulation of SLC35A1 expression or function could potentially enhance gene therapy outcomes. The differential effect on AAV serotypes (inhibiting AAV1-8 but enhancing AAV9 and AAV11 transduction) suggests serotype-specific optimization strategies .

• Patient stratification: Variations in SLC35A1 expression or function among individuals could potentially explain differential responses to gene therapy. Screening for SLC35A1 polymorphisms or expression levels might help predict treatment outcomes.

• Broadening beyond AAV: Investigating whether SLC35A1 affects trafficking of other viruses could reveal common mechanisms and potential therapeutic targets for infectious diseases.

• Structure-function insights: The finding that the C-terminal cytoplasmic tail of SLC35A1 is critical for AAV trafficking but not for sialic acid transport suggests distinct functional domains that could be targeted separately .

• Cellular trafficking pathways: Further research into how SLC35A1 facilitates nuclear import of AAV vectors could reveal fundamental aspects of nucleocytoplasmic transport mechanisms.

What methodological advances are needed to better understand the dual functionality of SLC35A1 in transport and trafficking?

Further elucidating SLC35A1's dual roles will require innovative approaches:

• Structural biology: Obtaining high-resolution structures of SLC35A1, particularly in complex with transport substrates or trafficking machinery components, would provide crucial insights into how one protein performs these distinct functions.

• Domain-specific protein engineering: Developing more refined mutants beyond the ΔC Tail and T128A variants already studied could help map functional domains with greater precision.

• Temporal control systems: Technologies allowing rapid activation or inactivation of specific SLC35A1 domains would help distinguish immediate transport effects from longer-term trafficking consequences.

• Single-molecule imaging: Techniques to visualize individual SLC35A1 molecules in living cells could reveal dynamic associations with transport substrates versus trafficking machinery.

• Organelle-specific perturbation: Methods to selectively disrupt SLC35A1 function in specific cellular compartments would help determine where its trafficking function is most critical.

• Synthetic biology approaches: Creating minimal synthetic transporters with specific SLC35A1 domains could help determine which structural elements are necessary and sufficient for each function.

• Computational modeling: Molecular dynamics simulations of SLC35A1 could predict conformational changes associated with transport versus trafficking functions and guide experimental design.